Cited by 1,110Liver Disease Diagnosis and TreatmentInflammasome and immune disordersLiver physiology and pathology

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice

Open access

Mridha, Auvro R., Wree, Alexander, Robertson, Avril A.B., Yeh, Matthew M., Johnson, Casey D., Van Rooyen, Derrick M., Haczeyni, Fahrettin, Teoh, Narci C.-H., Savard, Christopher, Ioannou, George N., Masters, Seth L., Schroder, Kate, Cooper, Matthew A., Feldstein, Ariel E., Farrell, Geoffrey C.·2017·Journal of Hepatology

DOI 10.1016/j.jhep.2017.01.022PMC PMC6536116

Open this paper in CoChat — free account

Abstract

Background & aims NOD-like receptor protein 3 (NLRP3) inflammasome activation occurs in Non-alcoholic fatty liver disease (NAFLD). We used the first small molecule NLRP3 inhibitor, MCC950, to test whether inflammasome blockade alters inflammatory recruitment and liver fibrosis in two murine models of steatohepatitis.Methods We fed foz/foz and wild-type mice an atherogenic diet for 16weeks, gavaged MCC950 or vehicle until 24weeks, then determined NAFLD phenotype. In mice fed an methionine/choline deficient (MCD) diet, we gavaged MCC950 or vehicle for 6weeks and determined the effects on liver fibrosis.Results In vehicle-treated foz/foz mice, hepatic expression of NLRP3, pro-IL-1β, active caspase-1 and IL-1β increased at 24weeks, in association with cholesterol crystal formation and NASH pathology; plasma IL-1β, IL-6, MCP-1, ALT/AST all increased. MCC950 treatment normalized hepatic caspase 1 and IL-1β expression, plasma IL-1β, MCP-1 and IL-6, lowered ALT/AST, and reduced the severity of liver inflammation including designation as NASH pathology, and liver fibrosis. In vitro, cholesterol crystals activated Kupffer cells and macrophages to release IL-1β; MCC950 abolished this, and the associated neutrophil migration. MCD diet-fed mice developed fibrotic steatohepatitis; MCC950 suppressed the increase in hepatic caspase 1 and IL-1β, lowered numbers of macrophages and neutrophils in the liver, and improved liver fibrosis.Conclusion MCC950, an NLRP3 selective inhibitor, improved NAFLD pathology and fibrosis in obese diabetic mice. This is potentially attributable to the blockade of cholesterol crystal-mediated NLRP3 activation in myeloid cells. MCC950 reduced liver fibrosis in MCD-fed mice. Targeting NLRP3 is a logical direction in pharmacotherapy of NASH.Lay summary Fatty liver disease caused by being overweight with diabetes and a high risk of heart attack, termed non-alcoholic steatohepatitis (NASH), is the most common serious liver disease with no current treatment. There could be several causes of inflammation in NASH, but activation of a protein scaffold within cells termed the inflammasome (NLRP3) has been suggested to play a role. Here we show that cholesterol crystals could be one pathway to activate the inflammasome in NASH. We used a drug called MCC950, which has already been shown to block NLRP3 activation, in an attempt to reduce liver injury in NASH. This drug partly reversed liver inflammation, particularly in obese diabetic mice that most closely resembles the human context of NASH. In addition, such dampening of liver inflammation in NASH achieved with MCC950 partly reversed liver scarring, the process that links NASH to the development of cirrhosis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2017.01.022

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The Inflammasomes
Schroder, K., & Tschopp, J. (2010) · Cell · doi:10.1016/j.cell.2010.01.040 · Cited by 5,475
Self-citation
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., Abela, G. S., Franchi, L., Nuñez, G., Schnurr, M., et al. (2010) · Nature · doi:10.1038/nature08938 · Cited by 4,026
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases
Coll, R. C., Robertson, A. A. B., Chae, J. J., Higgins, S. C., Muñoz-Planillo, R., Inserra, M. C., Vetter, I., Dungan, L. S., Monks, B. G., Stutz, A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3806 · Cited by 2,849
Self-citation
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W. Z., Strowig, T., Thaiss, C. A., Kau, A. L., Eisenbarth, S. C., Jurczak, M. J., et al. (2012) · Nature · doi:10.1038/nature10809 · Cited by 2,435
A lipidomic analysis of nonalcoholic fatty liver disease
Puri, P., Baillie, R. A., Wiest, M. M., Mirshahi, F., Choudhury, J., Cheung, O., Sargeant, C., Contos, M. J., & Sanyal, A. J. (2007) · Hepatology · doi:10.1002/hep.21763 · Cited by 1,338
Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites†
Neuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.23719 · Cited by 1,077
Cholesterol Crystals Activate the NLRP3 Inflammasome in Human Macrophages: A Novel Link between Cholesterol Metabolism and Inflammation
Rajamäki, K., Lappalainen, J., Öörni, K., Välimäki, E., Matikainen, S., Kovanen, P. T., & Eklund, K. K. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011765 · Cited by 1,039
NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice
Wree, A., Eguchi, A., McGeough, M. D., Pena, C. A., Johnson, C. D., Canbay, A., Hoffman, H. M., & Feldstein, A. E. (2014) · Hepatology · doi:10.1002/hep.26592 · Cited by 945
Self-citation
Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and Clinical Implications
Cusi, K. J. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.02.003 · Cited by 940

Flagged first, then by citations

Show all 49 references

Sorted by citations

Items 801–900 of 999

Liver fibrosis pathologies and potentials of RNA based therapeutics modalities
Diwan, R., Gaytan, S. L., Bhatt, H. N., Pena‐Zacarias, J., & Nurunnabi, M. (2024) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01551-8 · Cited by 6
Mechanisms of Inflammasome Activation and Involvement in Liver Disease
Baral, A. (2024) · Journal of Molecular Pathology · doi:10.3390/jmp5020011 · Cited by 6
Les mécanismes de mort cellulaire dans la stéatohépatite non alcoolique
Magusto, J., Majdi, A., & Gautheron, J. (2020) · Biologie Aujourd hui · doi:10.1051/jbio/2020002 · Cited by 7
Immune Mechanisms and Related Targets for the Treatment of Fibrosis in Various Organs
Pinar, A. A., & Samuel, C. S. (2022) · Current Molecular Medicine · doi:10.2174/1566524022666220114122839 · Cited by 7
Modulation of Nod-like Receptor Expression in the Thymus during Early Pregnancy in Ewes
Zhang, L., Li, Y., Zhao, Z., Cai, J., Zhao, S., & Yang, L. (2022) · Vaccines · doi:10.3390/vaccines10122128 · Cited by 6
Synthesis of deuterium-labelled analogues of NLRP3 inflammasome inhibitor MCC950
Salla, M., Butler, M. S., Massey, N. L., Reid, J. C., Cooper, M. A., & Robertson, A. A. B. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.12.054 · Cited by 7
Self-citation
Recent Advances in Hepatic Metabolic Regulation by the Nuclear Factor Rev-erbɑ
Zhang, Q., Chen, Y., Li, J., Xia, H., Tong, Y., & Liu, Y. (2024) · Current Drug Metabolism · doi:10.2174/0113892002290055240212074758 · Cited by 5
Dietary sphingolipids and milk fat globule membrane: emerging roles in cardiometabolic health and muscle function
Park, D., Kim, H., Shin, H., & Imm, J. (2025) · Food Science and Biotechnology · doi:10.1007/s10068-025-01863-6 · Cited by 5
Role of NLRP3 in the metabolism of bile acids and gut microbiota in CCl4-induced liver fibrosis
Feng, S. Y., Tao, R., Xie, X., & Zhao, X. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.00148-25 · Cited by 5
Natural products targeting NLRP3 inflammasome for metabolic dysfunction-associated fatty liver disease: the known unknowns
Meng, J., Wang, Q., Wang, H., Shen, X., Qin, T., Zhao, W. H., Li, H., & Yuan, Z. (2025) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(25)60970-8 · Cited by 5
Characterization of the gut mycobiome in patients with non-alcoholic fatty liver disease and correlations with serum metabolome
Zheng, N., Wang, D., Xing, G., Gao, Y., Li, S., Liu, J., Kang, J., Sha, S., Cheng, L., Fan, S., et al. (2025) · BMC Microbiology · doi:10.1186/s12866-025-04348-y · Cited by 5
Hepatocyte‐Derived Extracellular Vesicles Deliver miR‐328‐3p to Trigger PP2A‐B56δ–Mediated p‐NLRP3 S295 ‐Dependent Metaflammation in Macrophages upon Microcystin‐LR Exposure
Wu, J., Zhang, X., Ma, X., Wei, Y., Wang, L., Du, Z., Xia, X., Che, L., Guo, D., Zheng, H., et al. (2025) · Advanced Science · doi:10.1002/advs.202507039 · Cited by 5
Advanced strategies based on nanomedicine for Liver fibrosis treatment
Zhang, L., Liu, T., Shen, H., Liu, B.-H., Mei, Y., Liu, Y., Chen, S., Ma, X., He, C., Hu, T., et al. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126437 · Cited by 7
Hyperoside attenuates NASH-associated liver fibrosis by modulating Flot2/TLR4 signaling and pyroptosis
Huang, P., Zhu, Y., Li, Z., Zeng, K., Qin, L., Hu, J., Zhang, T., Zhang, L., Liu, T., & Qin, J. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.116007 · Cited by 5
Impairment of Rab7-dependent STING degradation hampers HBV replication but accelerates disease progression in chronic hepatitis B comorbid with MASLD
Wu, W., Gao, Q., Hai, S., Li, X., Yu, B., Hu, J., Xu, F., Zheng, X., Wang, Y., Danzeng, A., et al. (2026) · Gut · doi:10.1136/gutjnl-2026-338065 · Cited by 6
Characteristics of metabolic inflammatory syndrome among inpatients with type 2 diabetes: A cross-sectional study in China
Li, R., Lü, B., Li, Q., Hu, J., Huang, Y., Wang, Y., Qin, G., Zhang, W., Su, Q., Zhu, J., et al. (2023) · Primary care diabetes · doi:10.1016/j.pcd.2023.11.001 · Cited by 5
Anti-Angiogenic and Anti-Scarring Dual Effect of Galectin-3 Inhibition in Mouse Models of Corneal Wound Healing
Cao, Z., Ramadan, A. M., Tai, A., Zetterberg, F. R., & Panjwani, N. (2023) · American Journal Of Pathology · doi:10.1016/j.ajpath.2023.11.018 · Cited by 5
Compatibility with Fructus Ligustri Lucidi Effectively Mitigates Idiosyncratic Liver Injury of Epimedii Folium by Modulating NOD-like Receptor Family Pyrin Domain Containing 3 Inflammasome Activation
Zhao, X., Wu, Z., Wang, Y., Xu, Y., Ye, X., Dong, X., Li, J., Lv, G.-J., Wang, S., Li, Y., et al. (2024) · World Journal of Traditional Chinese Medicine · doi:10.4103/wjtcm.wjtcm_61_24 · Cited by 6
Protective effect of MP-40 mitigates BDL-induced hepatic fibrosis by inhibiting the NLRP3-mediated pyroptosis
Wan, X., Fang, Y., Qin, M., Zheng, Q., Yang, Q., Peng, M., Hao, M., Wang, K., Zhao, R., Shi, Y., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1479503 · Cited by 5
Impact of occult hepatitis B virus infection and high-fat diet on hepatocellular carcinoma development
Chen, K., & Qu, C. (2024) · Hepatoma Research · doi:10.20517/2394-5079.2024.85 · Cited by 5
The Protective Role of Baicalin in the Regulation of NLRP3 Inflammasome in Different Diseases
Zhang, Q., Guo, S., & Wang, H. (2024) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-024-01597-y · Cited by 6
Deficiency of O-linked-glycosylation regulates activation of T cells and aggravates Concanavalin A-induced liver injury
Hao, X., Gao, M., He, L., Ye, X., Yang, J., Zhang, F., Liu, R., & Wei, H. (2020) · Toxicology · doi:10.1016/j.tox.2020.152411 · Cited by 5
Progress in the Correlation Between Inflammasome NLRP3 and Liver Fibrosis
Sun, M., Zhang, Y., Guo, A., Xia, Z., & Peng, L. (2023) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2023.00231 · Cited by 5
Molecular factors associated with regression of liver fibrosis of alcoholic etiology
Kiseleva, Y. V., Zharikov, Y. O., Maslennikov, R. V., Pavlov, C. S., & Nikolenko, V. N. (2021) · Terapevticheskii arkhiv · doi:10.26442/00403660.2021.02.200617 · Cited by 5
Vinpocetine represses the progression of nonalcoholic steatohepatitis in mice by mediating inflammasome components via NF-κB signaling
Zhu, Y., Tang, H., Zhao, H., Lu, J. G., Lin, K., Ni, J., Zhao, B., Wu, G., & Tan, C. (2023) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2023.07.006 · Cited by 5
Phosphocreatine alleviates liver fibrosis in diabetic mice by targeting TGF-β/Smad and α-SMA pathways
Wang, F. H., Qaed, E., Aldahmash, W., Mahyoub, M. A., Al-Mutairi, D. S., Tang, Z., & Almoiliqy, M. (2025) · Tissue and Cell · doi:10.1016/j.tice.2025.103013 · Cited by 4
Profile of NT-0527, a brain penetrant NLRP3 Inflammasome inhibitor suitable as an in vivo tool compound for neuroinflammatory disorders
Harrison, D., Billinton, A., Bock, M. G., Clarke, N. P., Digby, Z., Gabel, C. A., Lindsay, N. A., Reader, V., Scanlon, J., Smolak, P. J., et al. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00639b · Cited by 5
The Flavonoid Kaempferol Mitigates Periprosthetic Osteolysis by Regulating the NLRP3 Inflammasome and Balancing Bone Metabolism
Huang, C., Zhang, C., Luo, Y., Guo, L., Wu, Y., Shi, Q., Zhang, Y., Yang, C., Wang, B., Niu, J., et al. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70878 · Cited by 4
Targeting immune checkpoint therapy: The role of manganese in tumor immunotherapy
Lyu, X., Li, B., & Lin, Z. (2025) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2025.10.001 · Cited by 4
Platelets in Neonatal Sepsis: Beyond Clotting, from Silent Players to Immune Orchestrators
Sokou, R., Lianou, A., Tsantes, A. G., Petrou, E., Bonovas, S., Nikolopoulos, G. K., Tsantes, A. Ε., & Iacovidou, N. M. (2025) · Seminars in Thrombosis and Hemostasis · doi:10.1055/a-2731-2399 · Cited by 4
New Strategies for the Prevention and Control of Foodborne Mycotoxins: Glycyrrhizic Acid Enhances Antioxidant Capacity and Modulates the ROS/NF-κB/NLRP3 Pathway to Treat Zearalenone-Induced Lung Injury in Chickens
Wang, J., Qu, P., Wang, F., Qian, M., Li, Z., Guo, M., & Gao, X. (2025) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.5c10522 · Cited by 4
A physiological oxygen gradient liver-zonation-on-a-chip reveals HIF-2α intervention in hepatic lipotoxicity
Wang, Y., Li, X., Han, J., Kong, F., Xu, Z., Hu, H., & Wang, L. (2025) · Acta Biomaterialia · doi:10.1016/j.actbio.2025.11.044 · Cited by 7
Lactylation‐Driven YTHDC1 Alleviates MASLD by Suppressing PTPN22‐Mediated Dephosphorylation of NLRP3
Zhang, F., Zeng, L.-H., Zou, K., Lin, K., Yao, F., Song, J., Zhang, S., Feng, H., Yang, Z., Wang, C., et al. (2025) · Advanced Science · doi:10.1002/advs.202510192 · Cited by 4
cGAS-STING signaling pathway in MASLD and liver fibrosis
Xiao, Y., Ma, Y., Gan, C., Huang, Z., & Gao, J. (2026) · Journal of Molecular Medicine · doi:10.1007/s00109-025-02612-2 · Cited by 4
Mitochondrial Dysfunction in Metabolic-Syndrome-Related MASLD/MASH: Metabolic Mechanisms and Therapeutic Perspectives
Jin, J., & Yang, C. C.-K. (2026) · Metabolites · doi:10.3390/metabo16070489 · Cited by 5
MASLD and the cardiovascular-kidney-liver-metabolic syndrome
Angelidi, A. M., Boutari, C., Kokkorakis, M., Stefanakis, K., Mikhailidis, D. P., Jacob, G., & Mantzoros, C. S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag023 · Cited by 6
Pathological Connections between Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease
Liu, H., Zhang, C., & Xiong, J. (2022) · Kidney Diseases · doi:10.1159/000527834 · Cited by 5
CerS5 deficiency promotes liver fibrosis development in non-alcoholic fatty liver disease
Chen, J., Hao, Y., Xu, P., Bian, D., Han, L., Wu, X., Zhuang, Z., Wang, J., & Luo, Y. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.05.027 · Cited by 4
Bavachinin, a main compound of Psoraleae Fructus, facilitates GSDMD-mediated pyroptosis and causes hepatotoxicity in mice
Shi, W. M., Gao, Y., Yang, H., Li, H., Liu, T., Zhao, J., Wei, Z., Lin, L., Huang, Y., Guo, Y., et al. (2024) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2024.111133 · Cited by 6
Knockout of Trpc6 attenuates T2DM-induced liver injury and inflammation by inhibiting CN-NFAT2-NLRP3 signalling in mice
Liu, Y., Fu, Y., Wang, G., Su, Y., Sun, R., Zhou, H., Ji, P., Xu, H., Li, W., & Li, W. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.155894 · Cited by 4
Novel insights from meta-analysis: the efficacy of ginsenosides in non-alcoholic fatty liver disease
Hao, L., Peng, Q., Li, S., Hu, X., & Yan, H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1564852 · Cited by 4
Alpha Ketoglutaric Acid attenuates LPS Induced Inflammatory Response by Inhibiting the PKCε/MAPK/P65 Signaling Pathway and Inhibit Oxidative Stress in Kupffer Cells
Li, Y., Kuang, H., Fan, G., & Yang, X. (2025) · Inflammation · doi:10.1007/s10753-025-02308-2 · Cited by 4
Oroxyloside inhibits liver fibrosis and hepatocarcinogenesis dependent on hepatocyte-specific knockout of Atg5
Liu, Y., Chen, L., Liu, X., Tao, R. N., Dong, R., Wang, X., Luo, J., Li, H., Zheng, Y., Qiang, L., et al. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157053 · Cited by 4
Deciphering the Role of Oroxylin A in Liver Fibrosis
Wang, S., Wu, J., Sun, J., Chen, W., Tian, Z., Huang, S., & Wang, M. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s530387 · Cited by 4
Protective effects of Dendrobium candidum Wall ex Lindl. on high‐fat diet‐induced liver damage in mice
Yin, X., Chi, W., Zhang, L., Su, Y.-X., Zhang, Z., & Xue, C. (2021) · Journal of Food Biochemistry · doi:10.1111/jfbc.13687 · Cited by 4
Therapeutic effect of fenofibrate for non-alcoholic steatohepatitis in mouse models is dependent on regime design
Wang, X., Luo, J., Lu, Z., Fang, S., Sun, M., Luo, W., Shen, J., Liu, A., & Ye, H. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1190458 · Cited by 6
Hepatic SPARC Expression Is Associated with Inflammasome Activation during the Progression of Non-Alcoholic Fatty Liver Disease in Both Mice and Morbidly Obese Patients
Onorato, A. M., Mauriz, L. L., Bayo, J., Fiore, E. J., Cantero, M. J., Bueloni, B., García, M. G., Lagües, C., Martinez‐Duartez, P., Menaldi, G., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914843 · Cited by 4
The Protective Effects of Cinnamyl Alcohol Against Hepatic Steatosis, Oxidative and Inflammatory Stress in Nonalcoholic Fatty Liver Disease Induced by Childhood Obesity
Dai, Y., Zhang, X., Xu, Y., Wu, Y., & Yang, L. (2023) · Immunological Investigations · doi:10.1080/08820139.2023.2280248 · Cited by 6
The Coptidis Rhizoma and Bovis Calculus herb pair attenuates NASH and inhibits the NLRP3 inflammasome activation
Xu, T., Chen, J., Shao, Q., Ji, J., Wang, Q., Ma, C., Wang, X., & Cheng, F. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e34718 · Cited by 4
Discovery, synthesis, and biological mechanism evaluation of novel quinoline derivatives as potent NLRP3 inhibitors
Wu, R., Yan, Y., Liu, Z., Zhang, X., Luo, Y., Liang, X., Lin, J., Zeng, X., Wu, D., Sun, P., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117466 · Cited by 4
Update in non-alcoholic fatty liver disease management: role of sodium-glucose cotransporter 2 inhibitors
Zambrano-Vásquez, O. R., Cortés-Camacho, F., Castañeda‐Sánchez, J. I., Aréchaga-Ocampo, E., Valle-Velázquez, E., Cabrera-Angeles, J. C., Sánchez-Gloria, J. L., Sánchez‐Muñoz, F., Arellano-Buendía, A. S., Sánchez‐Lozada, L. G., et al. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123638 · Cited by 5
[Pathogenic role of NDUFA13 inactivation in spontaneous hepatitis in mice and the mechanism].
Xu, X., Li, R., Zeng, X. Y., Wang, X., Xue, B., Huang, D., & Huang, Y. (2021) · Europe PMC (PubMed Central) · doi:10.12122/j.issn.1673-4254.2021.01.07 · Cited by 4
Paeoniflorin inhibits lipopolysaccharide-induced inflammation in LO2 cells by regulating RhoA/NLRP3 pathway
Liu, H., Fafeng, Cheng, Tang, F., Wang, Y.-F., Liu, S., & Wang, X. (2021) · Journal of Traditional Chinese Medical Sciences · doi:10.1016/j.jtcms.2021.06.001 · Cited by 4
Downregulation of the NLRP3/Caspse-1 Pathway Ameliorates Ketamine-Induced Liver Injury and Inflammation in Developing Rats
Chen, X., Zhang, Z., Shen, M., Ma, X., Qiu, D., Li, S., & Gao, L. (2022) · Molecules · doi:10.3390/molecules27092931 · Cited by 5
Heterogeneous population of macrophages in the development of non-alcoholic fatty liver disease
Cho, Y. E., Kwon, Y. S., & Hwang, S. (2022) · Liver Research · doi:10.1016/j.livres.2022.06.001 · Cited by 6
Investigation of the role of NLRP3 inflammasome activation in new-generation BCR-ABL1 tyrosine kinase inhibitors-induced hepatotoxicity
Arzuk, E. (2024) · Toxicology Letters · doi:10.1016/j.toxlet.2024.08.007 · Cited by 4
Inhibiting Inflammasomes with Small Molecules
Robertson, A. A. B. (2018) · Experientia supplementum · doi:10.1007/978-3-319-89390-7_15 · Cited by 4
Self-citation
Non-alcoholic fatty liver disease as an independent factor of cardiometabolic risk of cardiovascular diseases
Garbuzenko, D. V., & Belov, D. V. (2021) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-194-10-22-34 · Cited by 4
Mechanisms of NLRP3 inflammasome in pathogenesis and progression of inflammation-related gastrointestinal diseases
Liu, F., Shao, B., Zhu, Y., Xue, X., & Wu, X. (2025) · PeerJ · doi:10.7717/peerj.19828 · Cited by 3
Mechanisms of innate immune cells in Metabolic dysfunction-associated steatotic liver disease
Yao, Y., Wu, Q., Fan, B., Peng, X., Sheng, M., & Wang, F. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1599748 · Cited by 4
Regulated necrosis at the crossroads of liver inflammation and cancer development
Vucur, M., Kondylis, V., Brož, P., & Luedde, T. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01147-8 · Cited by 6
STING agonists as antiviral agents
Nelson, T. S., & Ma, Z. (2025) · FEBS Letters · doi:10.1002/1873-3468.70251 · Cited by 6
Nanotherapeutic Interventions for Parkinson’s Disease: Modulating Pathogenic Mechanisms and Overcoming Therapeutic Obstacles
Yin, X., Wang, C., Lin, W., Huang, S., & Chen, T. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s570452 · Cited by 3
Hepatocyte PLAGL2 deficiency alleviates MASH through MYD88-licensed inactivation of inflammasome
Duan, R., Wang, X., Wang, Q., Zhou, X., Gao, S., Sun, Y., Feng, Q., Li, Z., Yang, Z., Ding, J., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.116942 · Cited by 3
1-O-acetylbritannilactone alleviates high-fat diet-induced fatty liver by covalently targeting NLRP3
Jin, T., Zhao, Y., Xu, T., Fang, Y., Cui, Y., Liu, W., Xiong, Y., Ye, J., Luo, W., Hong, B., et al. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116351 · Cited by 3
PERK drives aflatoxin B1-induced chicken cellular senescence by promoting NLRP3-mediated PANoptosis
Cheng, Y., Hu, Z.-Y., Si, H.-L., Wang, T.-H., Lou, M., Chen, M.-S., Wang, J.-X., Jiang, F.-W., Huang, Y.-F., Zheng, J., et al. (2026) · Journal of Advanced Research · doi:10.1016/j.jare.2026.05.031 · Cited by 3
NLRP3 inflammasome activation promotes liver inflammation and fibrosis in experimental biliary atresia
Wang, J., Du, M., Meng, L., He, S., Zhu, Y., Yang, Y., Ren, X., Huang, Y., Sun, S., Dong, R., et al. (2023) · Digestive and Liver Disease · doi:10.1016/j.dld.2023.08.039 · Cited by 3
Nootkatone suppresses TLR4/NF-κB/NLRP3 pathway to alleviate non-alcoholic fatty liver disease via modulating gut microbiota
Fu, R., Xue, W., Liang, J., Wang, L., Zhang, M., & Meng, J. (2024) · Food Science and Human Wellness · doi:10.26599/fshw.2024.9250086 · Cited by 3
Gastroprotective Effect of Linagliptin on Indomethacin-Induced Gastric Ulceration in Mice: Crosstalk Between Oxidative Stress and Inflammasome Pathways
Wally, M. E., & Aly, M. H. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00695 · Cited by 3
Induction of MASH-like pathogenesis in the Nwd1−/− mouse liver
Yamada, S., Ogawa, H., Funato, M., Kato, M., Nakadate, K., Mizukoshi, T., Kawakami, K., Kobayashi, R., Horii, T., Hatada, I., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-07717-5 · Cited by 3
Therapeutic targeting of myeloid cells in liver fibrosis: Mechanisms and clinical prospects
Wang, Y., Liu, Y., Chen, D., Liu, L., Sun, L., & Zhang, L. (2025) · Animal Models and Experimental Medicine · doi:10.1002/ame2.70053 · Cited by 3
Inhibition of Inflammatory Signals “HMGB1, NLRP3, TNF-α, IL-1β” and Oxidative Stress in Diclofenac-Induced Hepatotoxicity in Rats Using Hydroalcoholic Extract of Dracocephalum kotschyi
Karimi-Dehkordi, M., Saghaei, F., & Hoseini, E. (2025) · Iranian journal of pharmaceutical research · doi:10.5812/ijpr-162656 · Cited by 3
Fatty acid mediators and the inflammasome
Desmarais, F., Bergeron, K., Ntambi, J. M., Rassart, É., & Mounier, C. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819404-1.00011-7 · Cited by 3
The Role of Inflammasomes in COVID-19: Potential Therapeutic Targets
Sun, C., Zhao, H., Han, Y., Wang, Y., & Sun, X. (2022) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2022.0061 · Cited by 3
Impact of partial bile duct ligation with or without repeated magnetic resonance imaging examinations in mice
Chen, T., Zhou, Z.-Y., Liu, J., Zheng, L., Wang, Z.-W., Zhang, X., & Zeng, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-25318-8 · Cited by 3
Water-soluble protein from walleye pollock (Gadus chalcogrammus) suppresses lipopolysaccharide-induced inflammation by attenuating TLR4–MyD88 expression in macrophages
Ono, M., Watari, S., Nishizawa-Higashi, M., Konishi, T., Takahashi, Y., Saeki, H., & Joe, G. (2023) · Food Chemistry Molecular Sciences · doi:10.1016/j.fochms.2023.100165 · Cited by 3
GPRC5A regulates proliferation and oxidative stress by inhibiting the STAT3/Socs3/c-MYC pathway in hepatocellular carcinoma
Zhang, L., Yang, W., Yang, J., & Sun, F. (2023) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.22-125 · Cited by 3
iTRAQ-based quantitative proteomics analysis of the effect of ACT001 on non-alcoholic steatohepatitis in mice
Zhou, H., Niu, B., Wu, X., Chu, W., Zhou, Y., Chen, Z., Mi, Y., Liu, Y., & Li, P. (2023) · Scientific Reports · doi:10.1038/s41598-023-38448-4 · Cited by 3
NLRP3 inflammasome inhibition decreases Schistosomiasis japonica -induced granulomatous inflammation and fibrosis in BALB/c mice
Lu, Y., Liu, J., Tang, W.-X., & Zhang, H. (2024) · Infection and Immunity · doi:10.1128/iai.00055-24 · Cited by 4
Unveiling the nexus: pyroptosis and its crucial implications in liver diseases
Miao, Z., Zhang, X., Xu, Y., Liu, Y., & Yang, Q. F. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-05147-1 · Cited by 3
Evaluation of the efficacy of cell-penetrating monoclonal antibodies targeting intracellular p-NLRP3S295 in alleviating hepatotoxicant-induced NAFLD.
Wu, J., He, Y.-Q., Wei, Y.-Y., Ma, X.-Y., Zhang, X.-Y., He, J., Wang, L.-L., He, J.-X., Han, Y., Lin, Z.-N., et al. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.142696 · Cited by 3
From “two hit theory” to “multiple hit theory”: Implications of evolution of pathogenesis concepts for treatment of non-alcoholic fatty liver disease
Liu, Q., & Niu, C.-Y. (2019) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v27.i19.1171 · Cited by 3
Nonalcoholic Fatty Liver Disease
Alazawi, W., & Hirschfield, G. M. (2020) · Springer eBooks · doi:10.1007/978-3-030-51709-0_21 · Cited by 3
Inhibition of plasminogen suppresses fibrosis and macrophage foaming in a nonalcoholic steatohepatitis mouse model
Tomonari, Y., Iwaki, T., Arakawa, T., & Umemura, K. (2022) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12774 · Cited by 3
Negative regulatory mechanisms of NLRP3 inflammasome
Zhao, W., & Ying, Q. I. N. (2018) · Scientia Sinica Vitae · doi:10.1360/n052018-00156 · Cited by 3
Altered cleavage of Caspase-1 in hepatocytes limits control of malaria in the liverPreprint
Marques-da-Silva, C., Poudel, B., Baptista, R. P., Peissig, K. B., Hancox, L. S., Shiau, J. C., Pewe, L. L., Shears, M. J., Kanneganti, T., Sinnis, P., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.28.427517 · Cited by 3
Targeting macrophages in liver fibrosis
González del Barrio, L., Ipsen, D. H., Pfister, D. R., Hancz, D., & Scott, C. L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1835489 · Cited by 3
Lipid Metabolism and Immune Response in Hepatocellular Carcinoma: Interplay Driving Tumor Progression
Yu, T. C.-Y., Tsui, Y., Zhang, V. X., Ma, H., & Ng, I. O. (2025) · Cancer Heterogeneity and Plasticity · doi:10.47248/chp2502020006 · Cited by 2
5‐Heptadecylresorcinol ameliorates high‐fat diet induced non‐alcoholic fatty liver disease through modulating bile acid profile and suppressing inflammation
Yang, Z., Hao, Y., Wang, Z., Wang, Z., Ye, G., Gao, F., Wang, J., & Liu, J. (2025) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.70060 · Cited by 2
CDK5RAP3 Deficiency Is Associated with Hepatic Inflammation and Increased Expression of NLRP3 Inflammasome Components
Chen, X., Huang, Y., Wu, Y., Sheng, L., Yan, H., Chen, F., Li, F., Ketema, H., & Cai, Y. (2025) · Biomedicines · doi:10.3390/biomedicines13082030 · Cited by 2
Loss of LCAT function aggravates metabolic-associated steatohepatitis (MASH) in golden Syrian hamster
Zhang, Y., Wang, H., Wang, F., Guo, X., Zhao, M., Zhou, Z., Lin, X., Zheng, L., Wang, Y., Liu, C., et al. (2025) · Clinical Science · doi:10.1042/cs20257764 · Cited by 2
PROM2 exacerbates CCl4-Induced liver fibrosis via NLRP3 inflammasome activation and hepatocyte pyroptosis
Guo, J., Lin, Y., Gong, X., Kuang, G., Hu, J., Du, H., Liu, H., Zhang, J., Zhang, L., Wan, J.-Y., et al. (2025) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-025-05920-5 · Cited by 3
NLRPs and tumor: research progress from molecular mechanisms to clinical applications
Song, L., Cao, Y., & Tao, Y. (2025) · Oncogene · doi:10.1038/s41388-025-03642-3 · Cited by 2
Celastrol alleviates acute spinal cord injury by inhibiting microglial pyroptosis via the Neat1/NLRP3 pathway
Wu, W., Zhao, Z., Sun, C., Xiong, D., Ru, Y., Li, C., He, Z., Dai, W.-Y., & Wang, J. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.153067 · Cited by 2
Recent advances in non-alcoholic steatohepatitis-associated hepatocellular carcinoma: immune cells, metabolic dysregulation, and therapeutic strategies
Liu, L., Duan, X., & Ju, B.-Z. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2025.1744299 · Cited by 3
The “Immune Rebellion” from the Intestines to the Liver: A Vicious Cycle That Causes the Liver to Collapse
Wang, W.-T., Tian, J., Gao, S., Wang, M.-B., Luo, Y., & Li, X. (2026) · Metabolites · doi:10.3390/metabo16020092 · Cited by 2
Herbal intervention targeting NLRP3 inflammasome in the treatment of liver diseases
Mendon, A., Mishra, N., Jain, S., & Bhatt, L. K. (2026) · Next research. · doi:10.1016/j.nexres.2026.101457 · Cited by 2
Unveiling MASH: a comprehensive review highlighting experimental insights, molecular pathogenesis, and therapeutic approaches
Ezz-Eldin, Y. M., Azouz, A. A., Khalaf, M. M., & Ewees, M. G. (2026) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2026.2638333 · Cited by 2
Synthesis and pharmacological evaluation of brominated derivatives of natural product celastrol for treatment of hepatic fibrosis
Li, M.-Y., Li, Y., Wang, X., Shang, F.-F., Long, Y., Li, Y.-L., Wang, Z., Zhang, A., Zhang, H., Ding, C., et al. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118765 · Cited by 2
Galactose-decorated lipid nanoparticle-mediated delivery of a selective NLRP3 inhibitor attenuates hepatic inflammation in metabolic dysfunction-associated steatotic liver disease
Niu, C., Gao, W., Tan, M., Chen, Y., SHI, Y., Geng, Y., Tao, H., Xu, Z., Zhang, T., & Yang, J. (2026) · Journal of Materials Chemistry B · doi:10.1039/d5tb02289d · Cited by 2

Authors: Mridha, A. R., Wree, A., Robertson, A. A. B., Yeh, M. M., Johnson, C. D., Van Rooyen, D. M., Haczeyni, F., Teoh, N. C.-H., Savard, C., Ioannou, G. N., Masters, S. L., Schroder, K., Cooper, M. A., Feldstein, A. E., & Farrell, G. C.
Affiliations: Australian National University (AU)
University of California San Diego (US)
The University of Queensland (AU)
University of Washington (US)
Walter and Eliza Hall Institute of Medical Research (AU)
Corresponding author: Farrell, Geoffrey C.
ORCID: Mridha, Auvro R.
Wree, Alexander
Robertson, Avril A.B.
Yeh, Matthew M.
Johnson, Casey D.
Haczeyni, Fahrettin
Savard, Christopher
Ioannou, George N.
Masters, Seth L.
Schroder, Kate
Cooper, Matthew A.
Feldstein, Ariel E.
Venue: Journal of Hepatology
Publisher: Elsevier BV
Published: 2017-05
Volume: 66
Issue: 5
Pages: 1037-1046
ISSN: 0168-8278 (ISSN-L)
DOI: 10.1016/j.jhep.2017.01.022
PMC: PMC6536116
OpenAlex: W2585046292
Cited by: 1,110
References: 49
Citations by year: 2026: 117 · 2025: 147 · 2024: 126 · 2023: 150 · 2022: 160 · 2021: 143 · 2020: 121 · 2019: 61 · 2018: 70 · 2017: 14
FWCI: 57.20
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Journal of Hepatology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
ANU Open Research (Australian National University) (submittedVersion, cc-by-nc-nd)
RWTH Publications (RWTH Aachen) (submittedVersion)
Funders: National Institute on Alcohol Abuse and Alcoholism (U01AA022489, R21AA023574)
National Institute of Diabetes and Digestive and Kidney Diseases (R01DK113592)
Topics: Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords: NLRP3 inflammasome, MCC950, nonalcoholic steatohepatitis, liver fibrosis, liver inflammation, IL-1β, caspase-1, cholesterol crystals, Kupffer cells, macrophages, neutrophil migration, methionine-choline-deficient diet, atherogenic diet, myeloid cells
MeSH terms: NLR Family, Pyrin Domain-Containing 3 Protein, Animals, Disease Models, Animal, Female, Furans, Hepatitis, Heterocyclic Compounds, 4 or More Rings, Indenes, Liver Cirrhosis, Experimental, Sulfonamides, Sulfones, NF-kappa B, Reactive Oxygen Species, Mice, Interleukin-1beta, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks